Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Giulia Demarzo

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
European Journal of Clinical Investigation|April 16, 2020
Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver diseaseEdoardo G Giannini, Costanza De Maria, Mattia Crespi, et al.
Expert Review of Gastroenterology & Hepatology|September 22, 2021
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disordersVincenzo Savarino, Luca Antonioli, Matteo Fornai, et al.
European Journal of Gastroenterology & Hepatology|August 2, 2021
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniquesGiorgia Bodini, Maria Giulia Demarzo, Afscin Djahandideh, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 8, 2020
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisationEdoardo G Giannini, Mattia Crespi, Afscin Djahandideh, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 20, 2022
The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's diseaseFabio Salvatore Macaluso, Mauro Grova, Marica Saladino, et al.
Scientific Reports|May 15, 2021
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originatorLinda Cingolani, Brigida Barberio, Fabiana Zingone, et al.
Therapeutic Advances in Gastroenterology|August 5, 2021
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian studyBrigida Barberio, Linda Cingolani, Cristina Canova, et al.
Inflammatory Bowel Diseases|April 2, 2020
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte RatioLorenzo Bertani, Federico Rossari, Brigida Barberio, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
European Journal of Clinical Investigation|April 16, 2020
Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver diseaseEdoardo G Giannini, Costanza De Maria, Mattia Crespi, et al.
Expert Review of Gastroenterology & Hepatology|September 22, 2021
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disordersVincenzo Savarino, Luca Antonioli, Matteo Fornai, et al.
European Journal of Gastroenterology & Hepatology|August 2, 2021
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniquesGiorgia Bodini, Maria Giulia Demarzo, Afscin Djahandideh, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 8, 2020
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisationEdoardo G Giannini, Mattia Crespi, Afscin Djahandideh, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 20, 2022
The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's diseaseFabio Salvatore Macaluso, Mauro Grova, Marica Saladino, et al.
Scientific Reports|May 15, 2021
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originatorLinda Cingolani, Brigida Barberio, Fabiana Zingone, et al.
Therapeutic Advances in Gastroenterology|August 5, 2021
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian studyBrigida Barberio, Linda Cingolani, Cristina Canova, et al.
Inflammatory Bowel Diseases|April 2, 2020
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte RatioLorenzo Bertani, Federico Rossari, Brigida Barberio, et al.
Pageof 2